Growth PotentialAnalyst's recommendation remains 'Outperform', indicating confidence in the company's growth potential.
Market ShareHeplisav has continued to gain and maintain market share, with an estimated share of the U.S. HBV market increasing to ~43% in Q1.
ProfitabilityHeplisav-B gross margin was 82% in 4Q24, indicating strong profitability from the product.